CARLOTA ROCA MARTINEZ

Dr. CARLOTA ROCA MARTINEZ


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CMCARLOTA ROCA MARTINEZ
CARLOTA ROCA MARTINEZ
YAYunuen Avalos-Padilla
Yunuen Avalos-Padilla
Beatriz Prieto-SimónBeatriz Prieto-Simón
Beatriz Prieto-Simón
VIValentín Iglesias
Valentín Iglesias
MRMiriam Ramirez
Miriam Ramirez
Xavier Fernàndez-BusquetsXavier Fernàndez-Busquets
Xavier Fernàndez-Busquets
The methyl erythritol phosphate (MEP) pathway of isoprenoid biosynthesis is essential for malaria parasites and also for several human pathogenic bacteria, thus representing an interesting target for future antimalarials and antibiotics and for diagnostic strategies. We have developed a DNA aptamer (D10) against Plasmodium falciparum 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR), the second enzyme of this metabolic route. D10 binds in vitro to recombinant DXR from P. falciparum and Escherichia coli, showing at 10 µM a ca. 50% inhibition of the bacterial enzyme. In silico docking analysis indicates that D10 associates with DXR in solvent-exposed regions outside the active center pocket. According to fluorescence confocal microscopy data, this aptamer specifically targets in P. falciparum in vitro cultures the apicoplast organelle where the MEP pathway is localized and is, therefore, a highly specific marker of red blood cells parasitized by Plasmodium vs. naïve erythrocytes. D10 is also selective for the detection of MEP+ bacteria (e.g., E. coli and Pseudomonas aeruginosa) vs. those lacking DXR (e.g., Enterococcus faecalis). Based on these results, we discuss the potential of DNA aptamers in the development of ligands that can outcompete the performance of the well-established antibody technology for future therapeutic and diagnostic approaches.